MedTrace Logo

Effect of Belimumab on Antibody Titers in Primary APS Patients

NCT06747312 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-12-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the regulatory effect of Belimumab on the antiphospholipid antibody (aPL) as well as to observe related past and new clinical events in primary antiphospholipid syndrome patients.

Conditions

  • Antiphospholipid Syndrome (APS)

Interventions

DRUG

Belimumab+SOC

10mg/kg once a month for 18 months

DRUG

SOC

SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2026-05-31
Completion
2027-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06747312 on ClinicalTrials.gov